1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Discovery and Unknown stages are 4, 1, 1, 1 and 1 respectively.
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
- Aronora Inc
- Bayer AG
- BioAegis Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Eagle Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- KidneyCure Ltd
- VESSL Therapeutics Ltd
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
- Featured News & Press Releases
- Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis
- Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator osocimab in patients with advanced renal disease completed
- Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in hemodialysis patients
- Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Eagle Pharmaceuticals Inc, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2022
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2022
- Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aronora Inc
- Bayer AG
- BioAegis Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Eagle Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- KidneyCure Ltd
- VESSL Therapeutics Ltd
